$375 Million is the total value of MPM BioImpact LLC's 32 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ONCR | Exit | Oncorus, Inc. | $0 | – | -2,377,031 | -100.0% | -0.02% | – |
Exit | Ventyx Biosciences Inc | $0 | – | -31,747 | -100.0% | -0.21% | – | |
HARP | Exit | Harpoon Therapeutics, Inc. | $0 | – | -3,196,707 | -100.0% | -0.46% | – |
EWTX | Exit | Edgewise Therapeutics Inc | $0 | – | -712,798 | -100.0% | -1.11% | – |
RETA | Exit | Reata Pharmaceuticals, Inc. | $0 | – | -234,478 | -100.0% | -4.81% | – |
KDNY | Exit | Chinook Therapeutics, Inc. | $0 | – | -1,003,406 | -100.0% | -7.76% | – |
ISEE | Exit | Iveric Bio Inc | $0 | – | -1,214,662 | -100.0% | -9.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
SC 13D/A | 2023-08-01 |
SC 13D | 2023-06-12 |
4 | 2023-06-05 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.